Dr Jonathan Kinlay

Jonathan Kinlay is the CEO of the investment research and consulting firm Investment Analytics, which he founded in 1998 before going on to establish the quantitative hedge fund Caissa Capital in 2002. He pioneered the use of advanced econometric models in volatility arbitrage strategies. The models, which provide the basis for the highly successful investment strategies used by Caissa Capital, are made available by Investment Analytics under license.

Mr. Kinlay is the CEO of the Proteom Capital Management Ltd, which offers sophisticated quantitative strategies using proprietary, state-of-the-art bioengineering technologies developed by the research partnership of Investment Analytics and Daytrends Inc.

Mr. Kinlay has consulted with leading investment funds and financial institutions in Europe and North America for over 20 years in the areas of financial engineering, investment strategy, quantitative analysis and risk management, initially with NatWest and Chase Manhattan banks and subsequently as the head of quantitative analytics and proprietary trading in a European hedge fund, where he traded US and European equities, fixed income and OTC & exchange traded derivatives. Mr. Kinlay has lectured at postgraduate level at a number of leading universities including, Carnegie Mellon University in New York, and Oxford, Cambridge and Reading Universities in the UK. He has postgraduate degrees in economics, statistics, and business administration from the universities of Bristol and Sheffield, and from the London Business School.

Dr Haftan Eckholdt

DayTrends was founded by Dr. Haftan Eckholdt. He has previous experience with “mission critical" computations where accuracy was essential. Working in labs funded by the National Institutes of Health, Department of Defense, and private pharmaceuticals, he has been an analyst on many longitudinal studies.

Some of the more critical models have included estimating effective doses of some of the world's most lethal toxins, and the design of subcortical brain maps used to guide neurosurgeons during deeply invasive procedures. His research in computational biology has focused on problems in genetics and neuroanatomy. Treating equity markets like genomes and neurological processes has allowed Dr. Eckholdt to apply his biological approach to finance.

Dr. Eckholdt has graduate degrees from Cornell and Columbia Universities in Cognitive, Developmental Psychology, and Biostatistics as well as a faculty appointment in Neuroscience at the Albert Einstein College of Medicine.